Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     
  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     
  • Bitcoin GBP

    50,425.69
    +56.90 (+0.11%)
     
  • CMC Crypto 200

    1,316.26
    +39.28 (+3.08%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

Here's Why Cogentix Medical Inc. Stock Is Surging Today

What happened

Shares of Cogentix Medical Inc. (NASDAQ: CGNT), a small-cap medical-device company, jumped this morning following a merger-agreement announcement. News of the impending acquisition by a subsidiary of Sweden's Investor AB has pushed the stock 14.2% higher as of 10:53 a.m. EDT on Monday.

So what

Investor AB's Laborie Medical Technologies subsidiary develops and markets pelvic-health-related devices, which makes Cogentix's flexible endoscopy products a perfect fit. In order to expand its offerings, Laborie offered a fairly standard 28% premium for all outstanding Cogentix Medical shares.

Man pointing to the tip of an upward sloping chart.
Man pointing to the tip of an upward sloping chart.

Image source: Getty Images.

ADVERTISEMENT

There probably won't be any room for arbitrageurs to scrape out a short-term gain. Cogentix is too small to register a blip on any antitrust regulator's radar, plus two investors that own a majority of the company have already agreed to tender their shares.

Now what

If you want to see how the company performed during its last quarter as Cogentix, you'll have to wait. Management won't be presenting fourth-quarter and full-year results today, as planned previously. The company will file an annual report with the U.S. Securities and Exchange Commission at the end of the month, but there won't be an earnings call or an associated press release.

Cogentix expects the transaction to close in the first half of the second quarter.

More From The Motley Fool

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.